Parapsoriasis e bua ka e 'ngoe ea lihlopha tsa mafu a letlalo a khethollang haholo-holo ka ho tšoana ha' ona le psoriasis (e khubelu, ea makhopho). Parapsoriasis ke lefu le sa tloaelehang la li‑lymphoproliferative dermatoses le hlahang haholo ho batho ba baholo ba lilemong tse mahareng, tseo 2/3 ea tsona e leng banna.
Kankere ea letlalo e ka hlaha ho tloha ho parapsoriasis. Ka mohlala, e ka fetoha lymphoma ea T‑cell ea letlalo (cutaneous T‑cell lymphoma).
○ Tlhahlobo le Kalafo Liteko tsa mali ho thibela syphilis Biopsy ho laola li‑lymphomas tsa letlalo
Parapsoriasis refers to one of a group of skin disorders that are characterized primarily by their resemblance to psoriasis (red, scaly lesions), rather than by their underlying cause.
Parapsoriasis is an uncommon inflammatory skin disease characterized by chronic patches that may be resistant to therapy. It was primarily introduced and classified 120 years ago, and the original classification incorporated parapsoriasis and pityriasis lichenoides under the umbrella term parapsoriasis. After a major change in classification, parapsoriasis now exclusively refers to small plaque parapsoriasis (SPP) and large plaque parapsoriasis (LPP). However, debates still frequently occur regarding various nomenclatures and classifications used by different authors. Moreover, parapsoriasis may progress to overt cutaneous lymphoma, most commonly mycosis fungoides (MF), and it is very difficult to distinguish these two conditions despite modern histologic and molecular testing techniques.
Parapsoriasis, presented as an early stage of cutaneous T-cell lymphoma, is mostly treated with psoralen and ultraviolet A (PUVA) therapy and narrowband ultraviolet B (NB-UVB) phototherapy.
Kankere ea letlalo e ka hlaha ho tloha ho parapsoriasis. Ka mohlala, e ka fetoha lymphoma ea T‑cell ea letlalo (cutaneous T‑cell lymphoma).
○ Tlhahlobo le Kalafo
Liteko tsa mali ho thibela syphilis
Biopsy ho laola li‑lymphomas tsa letlalo